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ABSTRACT 
 
Background: Atazanavir, an antiretroviral drug of the protease inhibitor class, is co-
administered with ritonavir to inhibit atazanavir metabolism and decrease pharmacokinetic 
variability. Atazanavir is metabolised mainly by CYP3A4/5 enzymes. High CYP3A 
intersubject variability has been documented in most cases on a genetic basis. The 
CYP3A5*3 allele affects splicing defect and protein truncation. Recently a new intronic 
variant, CYP3A4*22, was found associated with reduced CYP3A4 activity. To assess 
whether an altered CYP3A activity impairs the metabolism of atazanavir, we investigated 
the two functional polymorphisms. To the best of our knowledge, this is the first case 
report showing that overexposure to ATV is associated with CYP3A poor phenotype and 
nephrolithiasis. Further study is needed in order to confirm this interesting observation. 
Case Presentation: We describe the case of a 43 year-old HIV-1-infected man treated 
with atazanavir/ritonavir plus lamivudine who experienced early and recurrent severe 
episodes of kidney stones. Atazanavir plasma trough concentrations showed a value 
higher than the normal range, thus we investigated the two polymorphisms that are known 
to affect CYP3A4/5 activity. This analysis revealed that our patient was a CYP3A poor 
metabolizer since he carried CYP3A4*1/*22 and CYP3A5*3/*3 genotypes. 
Conclusion: We suggest that screening of CYP3A functional variants is an appropriate 
approach, helping in treatment choice and potential dosage adjustment of protease 
inhibitors. 
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1. BACKGROUND 
 
Whereas atazanavir (ATV) is well tolerated in most patients important side effects have been 
reported in the medium and long term [1]. In most European Countries ATV is approved only 
as ritonavir-boosted for the treatment of both antiretroviral naïve and experienced patients 
(ATV/r 300/100 mg qd). Other ways to administer ATV are formally considered as off-label. 
 
Considerable inter-individual variability has been observed in plasma concentrations of ATV 
after standard dosing [2], mainly related to drug-to-drug interactions and differences in 
hepatic metabolism. ATV is metabolised by hepatic CYP3A4/5 enzymes to a large extent, 
with 20% and 7% of unmodified drug being recovered in the feces and urine, respectively 
[3]. Atazanavir is also an inhibitor of CYP3A and UGT1A1; coadministration of atazanavir 
and drugs metabolised by CYP3A or UGT1A1 may result in adverse effects [3]. 
 
Genetic bases affect CYP3A activity and two polymorphisms have been suggested to play a 
key role in this. The first relevant variation is CYP3A5 intron 3 A>G single nucleotide 
polymorphism (SNP) commonly known as CYP3A5*3 allele, which results in a splicing 
defect and protein truncation [4]; whereas the overall allele frequency of the CYP3A5*3 allele 
is 31.2% it increases up to 97% in Caucasian population (1000 Genome Phase 1 genotype 
date). The second variation that recently has been shown to play a critical role in CYP3A4 
expression and activity is CYP3A4 intron 6 C>T polymorphism, also know as CYP3A4*22 
[5]; the overall allele frequency of the minor allele is 2.1% and 8% in Caucasian population 
(1000 Genome Phase 1 genotype date). 
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2. CASE PRESENTATION 
 
We report a case of a 43 years-old HIV-1-infected male patient enrolled in the AtLaS study. 
This is a pilot study evaluating the efficacy, safety an tolerability of treatment simplification to 
a dual therapy with atazanavir/ritonavir (rtv) plus lamivudine in virologically suppressed HIV+ 
patients [6].  
 
The AtLaS study was conducted in accordance with the Declaration of Helsinki and all 
subjects signed a written informed consent. 
 
Our patient had been receiving ATV/rtv + lamivudine + tenofovir for 4 years, had a CD4 cell 
count of 1,056/µL, an HIV-1 RNA < 50 cp/mL and a CDC stage A. This subject had a normal 
renal function (i.e. serum creatinine <1.0 mg/dL) and bever experienced problems with 
kidney stones. Upon enrollment, the subject experienced early (week 8) and recurrent 
severe kidney stones/colics. The episodes of drug-related nephrolithiasis were diagnosed 
indirectly after having excluded the presence of oxalate or urate crystals. ATV plasma trough 
concentration was assessed by a validated high performance liquid chromatographic (HPLC) 
method. As shown in Table 1, ATV trough level was very high being equal to 3,190 ng/mL 
(therapeutic range 150-850 ng/mL). The CYP3A5*3 and CYP3A4*22 alleles were evaluated 
by Real-Time PCR using LightSNiP (Roche). As expected, in Caucasian subject, the inactive 
CYP3A5*3 allele were found in homozygosis. Interestingly, our patient also was 
heterozygous for the CYP3A4*22 decrease-of-function allele, configuring a functional status 
of CYP3A poor metabolizer (Table 1).  
 
Table 1. Treatment monitoring and genotyping analysis performed in our case 
 
CD4 at 
BL (µL) 
HIV-RNA  
at BL 
(cp/mL) 
Age CD4  
Nadir 
BMI Week of 
kidney 
stones 
ATV 
Trough 
Levels* 
CYP3A4*22 rs 
35599367C>T 
CYP3A5*3 rs 
776746A>G 
1,056 49 43 238 27,43 8 3190 CT GG 
*Therapeutic range 150-850 ng/mL. BL: baseline, cp: copies. All genotypes were determined by Real-
Time PCR, using LightSNiP (Roche). CYP3A alleles associated to a poor metabolizer phenotype are 
reported in grey 
 
Other four out of the 40 patients enrolled in the ATLAS study became affected by kidney 
stones and/or clinically defined colics at a time later than our case. The ATV trough levels in 
these patients ranged from 1,150 to 1,900 ng/mL. Pharmacogenetic testing of their DNAs 
detected the CYP3A4 references allele and CYP3A5*3 in homozygous status defining them 
as belonging to the CYP3A intermediate phenotype. In one patient, the kidney stone has 
been analysed and ATV presence has been confirmed (7.9%-15.8% ATV in the composition 
of the stones) [7]. 
 
3. DISCUSSION 
 
Despite ATV being generally well tolerated, a higher incidence of renal stones among 
patients receiving ATV/rtv-containing antiretroviral therapy is reported [1]. Sometimes, cases 
of ATV-associated urolitiasis leading to obstructive uropathy and acute renal failure have 
been described [8]. Our patient experienced early severe and recurrent episodes of kidney 
stones. Recently, Nishijima and colleagues demonstrated that in HIV-1-infected Japanese 
patients, ATV-induced nephrolithiasis was associated with UGT1A-3′-UTR variants [9]. In 
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this respect two considerations need to be taken into account: firstly, the glucuronidation 
pathway represents a minor biotransformation pathway for ATV; secondly and more 
importantly, the ethnicity is an important factor influencing the genetic variability of the major 
ATV metabolic pathway. Indeed, the Caucasian population presents almost exclusively a 
CYP3A5*3/*3 genetic background and the activity of CYP3A5 is absent. The simultaneous 
determination of the common CYP3A4*22 allele, absent in Japanese population (1000 
Genome Phase 1 genotype date), may help to identify CYP3A poor metabolisers who can 
be at risk of early complications due to excessively high ATV concentration. Unmodified ATV 
is reported to be excreted in urine; the proportion of ATV in the urine increases and 
precipitation and renal stones formation may occur if ATV metabolism is reduced. To the 
best of our knowledge this is the first report showing that polymorphisms in CYP3A locus are 
likely to be involved in ATV overexposure and increase the risk of nephrolithiasis. Further 
studies are required to fully clarify the relationship between renal calculi induced by ATV and 
CYP3A genotypes. If our preliminary observation will be reconfirmed in a large series of 
patients receiving ATV/r based anti-HIV therapy, the identification of CYP3A4*22 and 
CYP3A5*3 alleles may help infectious disease physicians in prescribing a more adequate 
dose of ATV. This will prevent adverse events through the maintenance of an optimal viro-
immunologic efficacy. 
 
4. CONCLUSION 
 
To the best of our knowledge this is the first report showing that polymorphisms in CYP3A 
locus are likely to be involved in ATV overexposure and increase the risk of nephrolithiasis. 
Further studies are required to fully clarify the relationship between renal calculi induced by 
ATV and CYP3A genotypes. If our preliminary observation will be reconfirmed in a large 
series of patients receiving ATV/r based anti-HIV therapy, the identification of CYP3A4*22 
and CYP3A5*3 alleles may help infectious disease physicians in prescribing a more 
adequate dose of ATV. This will prevent adverse events through the maintenance of an 
optimal viro-immunologic efficacy. 
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